[go: up one dir, main page]

MA46661B1 - Formulations de vaccin glycoconjugué dirigé contre expec - Google Patents

Formulations de vaccin glycoconjugué dirigé contre expec

Info

Publication number
MA46661B1
MA46661B1 MA46661A MA46661A MA46661B1 MA 46661 B1 MA46661 B1 MA 46661B1 MA 46661 A MA46661 A MA 46661A MA 46661 A MA46661 A MA 46661A MA 46661 B1 MA46661 B1 MA 46661B1
Authority
MA
Morocco
Prior art keywords
directed against
vaccine formulations
expec
glycoconjugate vaccine
against expec
Prior art date
Application number
MA46661A
Other languages
English (en)
Other versions
MA46661A (fr
Inventor
Olga Labovitiadi
Wouter Tonnis
Francesco Doro
Janik Adriaansen
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of MA46661A publication Critical patent/MA46661A/fr
Publication of MA46661B1 publication Critical patent/MA46661B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des compositions et des méthodes pour induire une réponse immunitaire contre escherichia coli pathogène extra-intestinal (expec). En particulier, l'invention concerne des vaccins multivalents contenant un polysaccharide d'antigène e coli lié de manière covalente à une exotoxine a de protéine porteuse pseudomonas aeruginosa (epa) pouvant résister à de multiples contraintes environnementales.
MA46661A 2016-10-24 2017-10-24 Formulations de vaccin glycoconjugué dirigé contre expec MA46661B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16195256 2016-10-24
PCT/EP2017/077123 WO2018077853A1 (fr) 2016-10-24 2017-10-24 Formulations de vaccin glycoconjugué dirigé contre expec

Publications (2)

Publication Number Publication Date
MA46661A MA46661A (fr) 2019-08-28
MA46661B1 true MA46661B1 (fr) 2024-02-29

Family

ID=57206056

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46661A MA46661B1 (fr) 2016-10-24 2017-10-24 Formulations de vaccin glycoconjugué dirigé contre expec

Country Status (26)

Country Link
US (5) US10159751B2 (fr)
EP (1) EP3528839B1 (fr)
JP (1) JP6698220B2 (fr)
KR (1) KR102576346B1 (fr)
CN (1) CN109996559A (fr)
AR (1) AR109621A1 (fr)
AU (1) AU2017349163B2 (fr)
BR (1) BR112019007803A2 (fr)
CA (1) CA3038705A1 (fr)
CL (1) CL2019001104A1 (fr)
CO (1) CO2019003949A2 (fr)
EA (1) EA201991033A1 (fr)
ES (1) ES2966895T3 (fr)
HR (1) HRP20240171T1 (fr)
HU (1) HUE065328T2 (fr)
IL (1) IL266080B (fr)
MA (1) MA46661B1 (fr)
MX (2) MX2019004689A (fr)
MY (1) MY191842A (fr)
PH (1) PH12019500561B1 (fr)
PL (1) PL3528839T3 (fr)
RS (1) RS65125B1 (fr)
SG (1) SG11201902567WA (fr)
TW (1) TWI734853B (fr)
WO (1) WO2018077853A1 (fr)
ZA (1) ZA201902563B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2945651T (pt) 2013-01-17 2018-06-12 Arsanis Biosciences Gmbh Anticorpo específico para mdr e. coli
PL3110441T3 (pl) 2014-02-24 2024-08-05 Glaxosmithkline Biologicals S.A. Nowatorski polisacharyd i jego zastosowania
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
IL286467B1 (en) 2019-03-18 2025-10-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of E. COLI O-antigen polysaccharides, preparations thereof and methods for using them
IL286394B2 (en) 2019-03-18 2025-10-01 Janssen Pharmaceuticals Inc E. COLI O-antigen polysaccharide bioconjugates, methods for their production and methods for their use
JP7481585B2 (ja) 2020-09-17 2024-05-10 ヤンセン ファーマシューティカルズ，インコーポレーテッド 多価ワクチン組成物及びその使用
KR20240005684A (ko) 2021-04-08 2024-01-12 얀센 파마슈티칼즈, 인코포레이티드 바이오컨쥬게이트 생산 방법
EP4478050A1 (fr) 2023-06-12 2024-12-18 Janssen Pharmaceuticals, Inc. Procédé de quantification d'acétate lié dans des glycoconjugués

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3700612A (en) 1971-06-23 1972-10-24 Tenneco Chem Aqueous surface-coating compositions containing hydroxyalkyl ethers of galactomannan gums as thickeners
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422653D0 (en) 1984-09-07 1984-10-10 Technology Licence Co Ltd Monoclonal antibodies
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
AUPM399594A0 (en) 1994-02-21 1994-03-17 Csl Limited Antigenic preparation for treatment or prevention of helicobacter infection
FI102976B1 (fi) 1994-02-28 1999-03-31 Valtion Teknillinen Menetelmä lisäkeittokemikaalien tuottamiseen ja käyttämiseen sulfaattiprosessissa
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
EP1278548A2 (fr) 2000-04-18 2003-01-29 Endobiologics, Incorporated Vaccin conjugue anti-sepsie
RU2189253C1 (ru) 2001-04-09 2002-09-20 Государственный научный центр прикладной микробиологии Диагностикум для идентификации escherichia coli o157 : h7 и способ его получения
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
DE60303591T2 (de) 2002-03-07 2007-03-01 Eidgenössische Technische Hochschule Zürich System und methode zur herstellung von rekombinanten, glykosylierten protein in prokaryontischen wirtszellen
EP1517698B2 (fr) * 2002-06-21 2017-12-06 Novo Nordisk Health Care AG COMPOSITIONS SOLIDES STABILISEES DE POLYPEPTIDES DE FACTEUR VIIa
AU2003901008A0 (en) 2003-03-04 2003-03-20 Anadis Ltd Composition for the treatment and prevention of bacterial infections
ES2437565T3 (es) * 2003-06-30 2014-01-13 Alza Corporation Formulaciones para microproyecciones revestidas que contienen contraiones no volátiles
CN1950397B (zh) 2004-03-30 2012-05-16 Ns基因公司 生长因子NsG33的治疗用途
CA2567309A1 (fr) * 2004-06-01 2005-12-15 Ares Trading S.A. Procede de stabilisation de proteines
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
PL2311972T3 (pl) 2005-05-11 2015-08-31 Eth Zuerich Rekombinowane n-glikozylowane białka z komórek prokariotycznych
EP2007765B1 (fr) 2006-03-23 2012-06-27 Novartis AG Composes de potentialisation immunitaire
ES2376492T3 (es) 2006-03-23 2012-03-14 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores.
JP4791866B2 (ja) 2006-03-24 2011-10-12 国立大学法人秋田大学 下痢原性大腸菌感染症の判別に用いられる固相等
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
WO2009036379A2 (fr) 2007-09-14 2009-03-19 Adimab, Inc. Bibliothèques d'anticorps synthétiques rationnelles et leurs utilisations
WO2009089396A2 (fr) 2008-01-08 2009-07-16 Neose Technologies, Inc. Glycoconjugaison de polypeptides employant des oligosaccharyltransférases
PL2257307T3 (pl) 2008-02-20 2018-11-30 Glaxosmithkline Biologicals S.A. Biokoniugaty wytworzone z rekombinowanych n-glikozylowanych białek z komórek prokariotycznych
BRPI1014774A2 (pt) 2009-04-27 2019-04-16 Immuron Limited preparacao de imunoglobulina enriquecida anti-lps para uso no tratamento e/ou na profilaxia de um disturbio patologico
EP2475393A4 (fr) * 2009-09-14 2013-08-21 Vu Truong-Le Formulation pour la stabilisation à température ambiante d'un vaccin bactérien atténué vivant
AU2010322454B2 (en) 2009-11-19 2016-05-19 Glaxosmithkline Biologicals S.A. Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells
DK3336225T3 (da) 2010-07-16 2020-03-30 Adimab Llc Antistofbiblioteker
WO2012028315A1 (fr) * 2010-09-02 2012-03-08 Sanofi Pasteur Sa Agent stabilisant pour la préparation d'une composition de vaccin contre la poliomyélite, injectable, sèche
KR20140005892A (ko) 2010-12-10 2014-01-15 머크 샤프 앤드 돔 코포레이션 면역원성 조성물의 진탕-유도된 응집을 완화시키는 신규한 제제
EP3251692B1 (fr) * 2011-05-13 2023-09-27 Zoetis Services LLC Compositions immunogènes de glycoprotéine g de virus hendra et nipah
WO2013034664A1 (fr) 2011-09-06 2013-03-14 Glycovaxyn Ag Vaccins bioconjugués fabriqués dans des cellules procaryotes
CN103930436A (zh) * 2011-09-14 2014-07-16 诺华股份有限公司 大肠杆菌疫苗组合
US9932598B2 (en) 2012-08-02 2018-04-03 The Regents Of The University Of California Metabolic engineering of microbial organisms
BR112015004817A2 (pt) 2012-09-10 2017-07-04 Glycovaxyn Ag bioconjugados compreendendo antígenos modificados e seus usos
SG11201502638YA (en) 2012-10-12 2015-05-28 Glycovaxyn Ag Methods of host cell modification
ES2750525T3 (es) 2012-12-27 2020-03-26 Glaxosmithkline Biologicals Sa Procedimientos y composiciones relacionados con CRM197
PT2945651T (pt) 2013-01-17 2018-06-12 Arsanis Biosciences Gmbh Anticorpo específico para mdr e. coli
GB201301085D0 (en) * 2013-01-22 2013-03-06 London School Hygiene & Tropical Medicine Glycoconjugate Vaccine
EP2968535A2 (fr) * 2013-03-15 2016-01-20 Glaxosmithkline Intellectual Property (No. 2) Limited Formulations d'anticorps à faibles concentrations
JP2016533719A (ja) 2013-10-11 2016-11-04 グリコヴァキシン アーゲー 宿主細胞改変方法
PT3096785T (pt) * 2014-01-21 2020-10-13 Pfizer Composições imunogénicas que compreendem antigénios de sacáridos capsulares conjugados e utilizações das mesmas
CN113388032A (zh) 2014-02-06 2021-09-14 X4制药(奥地利)有限责任公司 大肠杆菌特异性抗体序列
PL3110441T3 (pl) 2014-02-24 2024-08-05 Glaxosmithkline Biologicals S.A. Nowatorski polisacharyd i jego zastosowania
HUE057726T2 (hu) 2014-12-30 2022-06-28 Glaxosmithkline Biologicals Sa Fehérje glikozilálására szolgáló készítmények és módszerek
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
IL286467B1 (en) 2019-03-18 2025-10-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of E. COLI O-antigen polysaccharides, preparations thereof and methods for using them
IL286394B2 (en) 2019-03-18 2025-10-01 Janssen Pharmaceuticals Inc E. COLI O-antigen polysaccharide bioconjugates, methods for their production and methods for their use

Also Published As

Publication number Publication date
CA3038705A1 (fr) 2018-05-03
MX2023004834A (es) 2023-05-10
US20240082412A1 (en) 2024-03-14
KR102576346B1 (ko) 2023-09-07
US10525145B2 (en) 2020-01-07
RS65125B1 (sr) 2024-02-29
HUE065328T2 (hu) 2024-05-28
ES2966895T3 (es) 2024-04-24
TW201817443A (zh) 2018-05-16
US10159751B2 (en) 2018-12-25
US20190105402A1 (en) 2019-04-11
SG11201902567WA (en) 2019-05-30
MA46661A (fr) 2019-08-28
US20210275681A1 (en) 2021-09-09
CO2019003949A2 (es) 2019-07-31
MY191842A (en) 2022-07-18
CN109996559A (zh) 2019-07-09
JP6698220B2 (ja) 2020-05-27
AU2017349163B2 (en) 2019-10-31
TWI734853B (zh) 2021-08-01
EA201991033A1 (ru) 2019-09-30
WO2018077853A1 (fr) 2018-05-03
KR20190101954A (ko) 2019-09-02
US20200101167A1 (en) 2020-04-02
CL2019001104A1 (es) 2019-06-21
PH12019500561A1 (en) 2019-11-25
AU2017349163A1 (en) 2019-04-11
HRP20240171T1 (hr) 2024-04-12
US11033633B2 (en) 2021-06-15
IL266080B (en) 2022-05-01
JP2019535678A (ja) 2019-12-12
EP3528839B1 (fr) 2023-11-08
NZ751736A (en) 2021-07-30
EP3528839C0 (fr) 2023-11-08
MX2019004689A (es) 2019-11-18
ZA201902563B (en) 2024-09-25
BR112019007803A2 (pt) 2019-09-03
EP3528839A1 (fr) 2019-08-28
PH12019500561B1 (en) 2023-12-06
US20180110870A1 (en) 2018-04-26
US11844766B2 (en) 2023-12-19
PL3528839T3 (pl) 2024-03-25
AR109621A1 (es) 2018-12-26
IL266080A (en) 2019-06-30

Similar Documents

Publication Publication Date Title
MA46661B1 (fr) Formulations de vaccin glycoconjugué dirigé contre expec
EP4245320A3 (fr) Méthodes et compositions pour une protection immunitaire contre e. coli pathogène extra-intestinale
EA201691478A1 (ru) Новый полисахарид и его применения
PH12021550319A1 (en) Escherichia coli compositions and methods thereof
MY206244A (en) Anti-muc1 antibody-drug conjugate
MY201701A (en) Optimized antibody compositions for treatment of ocular disorders
MX2010005871A (es) Anticuerpos al antigeno de pcrv de pseudomonas aeruginosa.
MA41265B1 (fr) Compositions pour administration de médicaments iléo-jéjunal.
WO2015130584A3 (fr) Adjuvants de vaccins sous forme de nanoparticules lipidiques et systèmes d'administration d'antigènes
NZ743964A (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
AR082952A1 (es) Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
EA201890417A1 (ru) Генетически кодируемые, внутренне неупорядоченные полимеры-"невидимки" для доставки и способы их применения
MX2022015734A (es) Proteinas de exotoxina a modificadas.
PH12023550020A1 (en) Multivalent vaccine compositions and uses thereof
MA45283A1 (fr) Une composition de multivalent pneumococcal la protéine de polysaccaride-transporteur capsulaire se conjugue et utilisez de cela
MA39228A1 (fr) Compositions à utiliser pour le traitement d'états allergiques
MX2015011692A (es) Suspension de proteinas como un sistema opacificante de bebidas.
MX2022001937A (es) Composicion inmunogenica.
AR105793A1 (es) Métodos y composiciones para protección inmunológica contra e. coli patogénica extraintestinal
AR116010A1 (es) Composiciones de escherichia coli y métodos de estas
AR114693A1 (es) Vacunas contra infecciones intraabdominales
PL408955A1 (pl) Immunogenny koniugat i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez pałeczki jelitowe z rodziny Enterobacteriaceae
AR125423A1 (es) Vacunas contra infecciones del tracto urinario
TH162727A (th) สารเพิ่มความเสถียรต่อแสงชนิดใหม่
MA38131A3 (fr) Thérapie adjuvante par inhibiteur de kinase de la famille tec